Clinical Trends for July 2017

Ryan Syrek


July 28, 2017

Each week, we identify one top search term, speculate as to what caused its popularity, and provide an infographic on a related condition. If you have thoughts about what's trending and why, feel free to share them with us on Twitter or Facebook!

Clinical Trend of the Week (July 22-28): Vitiligo

A potentially promising treatment for a fairly common condition is responsible for this week’s top search term. Vitiligo, which has a prevalence rate of 1%-2%, is notoriously difficult to treat. This is why the potential use of Janus kinase (JAK) inhibitors represents an exciting development. A recent proof-of-concept study found that twice-daily topical ruxolitinib 1.5% cream was associated with a 23% overall improvement in Vitiligo Area Scoring Index (VASI) totals. The scores were most improved for facial vitiligo, and side effects were mild. The next step is randomized, placebo controlled clinical trials that will help quantify the efficacy and clarify the safety. Further news is no doubt eagerly awaited by patients with vitiligo and those that treat them.

For more information on vitiligo, read here.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.